* 1. receipt of any vaccine (licensed or investigational) other than the study intervention within 30 days before and after each study vaccination (one week for licensed seasonal influenza vaccine or pneumococcal vaccine) * 2. prior or planned receipt of any other investigational or licensed vaccine or product likely to impact on interpretation of the trial data (e.g. adenovirus vectored vaccines, any coronavirus vaccines) * 3. positive sars-cov-2 rt-pcr at screening. * 4. participants who are pregnant at enrolment or planning to become pregnant during the first 3 months following vaccination. * 5. administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccines. * 6. any confirmed or suspected immunosuppressive or immunodeficient state; asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting ≤14 days). * 7. history of allergic disease or reactions likely to be exacerbated by any component of study vaccines. * 8. any history of anaphylaxis. * 9. current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).

* 1. receipt of any vaccine (licensed or investigational) other than the study intervention within 30 days before and after each study vaccination (one week for licensed seasonal influenza vaccine or pneumococcal vaccine) * 2. prior or planned receipt of any other investigational or licensed vaccine or product likely to impact on interpretation of the trial data (e.g. adenovirus vectored vaccines, any coronavirus vaccines) * 3. positive sars-cov-2 rt-pcr at screening. * 4. participants who are pregnant at enrolment or planning to become pregnant during the first 3 months following vaccination. * 5. administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccines. * 6. any confirmed or suspected immunosuppressive or immunodeficient state; asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting ≤14 days). * 7. history of allergic disease or reactions likely to be exacerbated by any component of study vaccines. * 8. any history of anaphylaxis. * 9. current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).

1. receipt of any vaccine (licensed or investigational) other than the study intervention within 30 days before and after each study vaccination (one week for licensed seasonal influenza vaccine or pneumococcal vaccine) 2. prior or planned receipt of any other investigational or licensed vaccine or product likely to impact on interpretation of the trial data (e.g. adenovirus vectored vaccines, any coronavirus vaccines) 3. positive sars-cov-2 rt-pcr at screening. 4. participants who are pregnant at enrolment or planning to become pregnant during the first 3 months following vaccination. 5. administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccines. 6. any confirmed or suspected immunosuppressive or immunodeficient state; asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting ≤14 days). 7. history of allergic disease or reactions likely to be exacerbated by any component of study vaccines. 8. any history of anaphylaxis. 9. current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).

1. receipt of any vaccine (licensed or investigational) other than the study intervention within 30 days before and after each study vaccination (one week for licensed seasonal influenza vaccine or pneumococcal vaccine) 2. prior or planned receipt of any other investigational or licensed vaccine or product likely to impact on interpretation of the trial data (e.g. adenovirus vectored vaccines, any coronavirus vaccines) 3. positive sars-cov-2 rt-pcr at screening. 4. participants who are pregnant at enrolment or planning to become pregnant during the first 3 months following vaccination. 5. administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccines. 6. any confirmed or suspected immunosuppressive or immunodeficient state; asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting ≤14 days). 7. history of allergic disease or reactions likely to be exacerbated by any component of study vaccines. 8. any history of anaphylaxis. 9. current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).